Table 2.

Relative risk of squamous cell (SCC) and adenocarcinoma of the cervix (AC) associated with C. trachomatis by enzyme linked immunsorbent assay (EIA), C. trachomatis serotypes by micrommunoflourescence (MIF), and C. pneumoniae by MIF

	Controls		SCC Cases				AC Cases
Antibody Test	n	%	n	%	OR	(95% CI)	n	%	OR	(95% CI)
C. Pneumoniae MIF
Negative	239	75.2	238	78.8	1.0	Ref.	143	77.3	1.0	Ref.
Positive	79	24.8	64	21.2	0.8	(0.5–1.2)	42	22.7	0.9	(0.6–1.4)
C. trachomatis EIA
Negative	235	73.9	186	61.6	1.0	Ref.	133	71.9	1.0	Ref.
Positive	83	26.1	116	38.4	1.6	(1.1–2.2)	52	28.1	1.0	(0.6–1.5)
C. trachomatis EIA and MIF
EIA −	235	73.9	186	61.6	1.0	Ref.	133	71.9	1.0	Ref.
EIA+ MIF−	48	15.1	47	15.6	1.1	(0.7–1.8)	26	14.1	0.9	(0.5–1.5)
EIA+ MIF+	35	11.0	69	22.8	2.3	(1.5–3.7)	26	14.1	1.1	(0.6–2.0)
C. trachomatis number of serotypes detected by MIF*
EIA −	235	87.0	186	72.9	1.0	Ref.	133	83.6	1.0	Ref.
1	8	3.0	17	6.7	2.6	(1.1–6.3)	3	1.9	0.5	(0.1–2.1)
2	11	4.1	17	6.7	1.8	(0.8–4.0)	10	6.3	1.4	(0.6–3.4)
3	9	3.3	14	5.5	1.9	(0.8–4.7)	7	4.4	1.1	(0.4–3.1)
4+	7	2.6	21	8.2	3.4	(1.4–8.4)	6	3.8	1.3	(0.4–4.1)
C. trachomatis MIF titers*
EIA −	235	87.0	186	72.9	1.0	Ref.	133	83.6	1.0	Ref.
MIF 1:16	10	3.7	16	6.3	1.8	(0.8–4.0)	4	2.5	0.6	(0.2–2.1)
MIF 1:32	11	4.1	17	6.7	2.0	(0.9–4.4)	7	4.4	0.9	(0.3–2.4)
MIF 1:64	14	5.2	36	14.1	3.1	(1.6–6.0)	15	9.4	1.6	(0.8–3.5)

Odds ratios (OR) are adjusted for sex partners (1, 2–4,5+) and age at reference (continuous).

^*Subjects with screening assay positive and microimmunoflourescence assay negative results (EIA+ MIF−; n=121) were excluded from these analyses.